Bonus BioGroup Ltd
Bonus BioGroup Ltd., a clinical-stage biotechnology company, develops products based on tissue engineering and cell therapy. The company's products under development include BonoFill for the treatment of bone tissue regeneration in maxillofacial and orthopedic indications, and defects in limb and jaw bones which is in Phase II clinical trial, as well as in a preclinical stage for the treatment of… Read more
Bonus BioGroup Ltd (BBIXF) - Total Liabilities
Latest total liabilities as of June 2025: $19.00 Million USD
Based on the latest financial reports, Bonus BioGroup Ltd (BBIXF) has total liabilities worth $19.00 Million USD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Bonus BioGroup Ltd - Total Liabilities Trend (2013–2024)
This chart illustrates how Bonus BioGroup Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Bonus BioGroup Ltd Competitors by Total Liabilities
The table below lists competitors of Bonus BioGroup Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ark Restaurants Corp
NASDAQ:ARKR
|
USA | $101.39 Million |
|
Companhia de Tecidos Norte de Minas
SA:CTNM3
|
Brazil | R$3.67 Billion |
|
Amines & Plasticizers Limited
NSE:AMNPLST
|
India | ₹1.21 Billion |
|
Chesapeake Granite Wash Trust
PINK:CHKR
|
USA | $0.00 |
|
Forgame Holdings Limited
F:FH0
|
Germany | €34.96 Million |
|
Global Menkul Degerler AS
IS:GLBMD
|
Turkey | TL2.16 Billion |
|
Africa Israel Residences Ltd
TA:AFRE
|
Israel | ILA2.82 Billion |
Liability Composition Analysis (2013–2024)
This chart breaks down Bonus BioGroup Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -11.35 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.10 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Bonus BioGroup Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Bonus BioGroup Ltd (2013–2024)
The table below shows the annual total liabilities of Bonus BioGroup Ltd from 2013 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $16.45 Million | +5.55% |
| 2023-12-31 | $15.58 Million | -14.47% |
| 2022-12-31 | $18.22 Million | -8.40% |
| 2021-12-31 | $19.89 Million | -4.15% |
| 2020-12-31 | $20.75 Million | +0.20% |
| 2019-12-31 | $20.71 Million | +55.31% |
| 2018-12-31 | $13.34 Million | +11.49% |
| 2017-12-31 | $11.96 Million | +16.59% |
| 2016-12-31 | $10.26 Million | +43.58% |
| 2015-12-31 | $7.14 Million | +82.32% |
| 2014-12-31 | $3.92 Million | +128.91% |
| 2013-12-31 | $1.71 Million | -- |